AgeX Therapeutics, Inc. AMEX:AGE

Founder-led company
Financial Health
0
1
2
3
4
5
6
7
8
9

AgeX Therapeutics stock price monthly change

-5.43%
month

AgeX Therapeutics stock price quarterly change

-35.41%
quarter

AgeX Therapeutics stock price yearly change

-38.57%
year

AgeX Therapeutics key metrics

Market Cap
27.75M
Enterprise value
31.08M
P/E
-2.19
EV/Sales
914.25
EV/EBITDA
-4.40
Price/Sales
708.34
Price/Book
-1.39
PEG ratio
0.10
EPS
-14.06
Revenue
116K
EBITDA
-10.01M
Income
-20.96M
Revenue Q/Q
-50%
Revenue Y/Y
197.43%
Profit margin
-30770.59%
Oper. margin
-20514.71%
Gross margin
61.76%
EBIT margin
-20514.71%
EBITDA margin
-8636.21%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

AgeX Therapeutics stock price history

AgeX Therapeutics stock forecast

AgeX Therapeutics financial statements

AgeX Therapeutics, Inc. (AMEX:AGE): Profit margin
Jun 2023 9K -2.66M -29655.56%
Sep 2023 46K -5.40M -11741.3%
Dec 2023 56K -3.45M -6171.43%
Mar 2024 5K -9.43M -188740%
AgeX Therapeutics, Inc. (AMEX:AGE): Debt to assets
Jun 2023 12277000 34.57M 281.61%
Sep 2023 12210000 39.85M 326.41%
Dec 2023 11965000 6.60M 55.22%
Mar 2024 10856000 15.16M 139.69%
AgeX Therapeutics, Inc. (AMEX:AGE): Cash Flow
Jun 2023 -2.01M 0 2M
Sep 2023 -1.86M 0 2M
Dec 2023 -2.05M 0 2M
Mar 2024 -1.57M -14K 2.72M

AgeX Therapeutics alternative data

AgeX Therapeutics, Inc. (AMEX:AGE): Employee count
Aug 2023 5
Sep 2023 5
Oct 2023 5
Nov 2023 5
Dec 2023 5
Jan 2024 5
Feb 2024 5
Mar 2024 4
Apr 2024 4
May 2024 4
Jun 2024 4
Jul 2024 4

AgeX Therapeutics other data

9.04% -3.58%
of AGE is owned by hedge funds
3.43M -1.35M
shares is hold by hedge funds

AgeX Therapeutics, Inc. (AMEX:AGE): Insider trades (number of shares)
Period Buy Sel
Feb 2022 308565 0
Transaction Date Insider Security Shares Price per share Total value Source
Option
WEST MICHAEL D officer: Chief Ex.. Restricted Stock Units 3,125 N/A N/A
Option
WEST MICHAEL D officer: Chief Ex.. Common Stock, $0.0001 par value 3,125 N/A N/A
Option
WEST MICHAEL D director, officer.. Restricted Stock Units 3,125 N/A N/A
Option
WEST MICHAEL D director, officer.. Common Stock, $0.0001 par value 3,125 N/A N/A
Option
WEST MICHAEL D director, officer.. Restricted Stock Units 3,125 N/A N/A
Option
WEST MICHAEL D director, officer.. Common Stock, $0.0001 par value 3,125 N/A N/A
Option
WEST MICHAEL D director, officer.. Restricted Stock Units 3,125 N/A N/A
Option
WEST MICHAEL D director, officer.. Common Stock, $0.0001 par value 3,125 N/A N/A
Option
WEST MICHAEL D director, officer.. Restricted Stock Units 3,125 N/A N/A
Option
WEST MICHAEL D director, officer.. Common Stock, $0.0001 par value 3,125 N/A N/A
Patent
Application
Filling date: 6 Dec 2021 Issue date: 26 May 2022
Application
Filling date: 17 Feb 2021 Issue date: 14 Apr 2022
Application
Filling date: 6 Dec 2021 Issue date: 24 Mar 2022
Application
Filling date: 6 Dec 2021 Issue date: 24 Mar 2022
Application
Filling date: 22 Jan 2021 Issue date: 4 Nov 2021
Application
Filling date: 23 Apr 2019 Issue date: 17 Jun 2021
Grant
Filling date: 3 Jun 2014 Issue date: 30 Mar 2021
Application
Filling date: 27 Mar 2020 Issue date: 1 Oct 2020
Application
Filling date: 27 Mar 2020 Issue date: 1 Oct 2020
Application
Filling date: 7 Jan 2020 Issue date: 16 Jul 2020
Insider Compensation
Dr. Michael D. West Ph.D. (1953) Founder, Pres, Chief Executive Officer & Director $561,030
Dr. Nafees Naseer Malik M.D. (1977) Chief Operating Officer $282,270
Ms. Eun-Jae Park CPA (1972) Chief Financial Officer
$277,350
  • When is AgeX Therapeutics's next earnings date?

    Unfortunately, AgeX Therapeutics's (AGE) next earnings date is currently unknown.

  • Does AgeX Therapeutics pay dividends?

    No, AgeX Therapeutics does not pay dividends.

  • How much money does AgeX Therapeutics make?

    AgeX Therapeutics has a market capitalization of 27.75M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 317.65% to 142K US dollars.

  • What is AgeX Therapeutics's stock symbol?

    AgeX Therapeutics, Inc. is traded on the AMEX under the ticker symbol "AGE".

  • What is AgeX Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of AgeX Therapeutics?

    Shares of AgeX Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are AgeX Therapeutics's key executives?

    AgeX Therapeutics's management team includes the following people:

    • Dr. Michael D. West Ph.D. Founder, Pres, Chief Executive Officer & Director(age: 72, pay: $561,030)
    • Dr. Nafees Naseer Malik M.D. Chief Operating Officer(age: 48, pay: $282,270)
    • Ms. Eun-Jae Park CPA Chief Financial Officer(age: 53, pay: $277,350)
  • Is AgeX Therapeutics founder-led company?

    Yes, AgeX Therapeutics is a company led by its founder Dr. Michael D. West Ph.D..

  • How many employees does AgeX Therapeutics have?

    As Jul 2024, AgeX Therapeutics employs 4 workers.

  • When AgeX Therapeutics went public?

    AgeX Therapeutics, Inc. is publicly traded company for more then 6 years since IPO on 29 Nov 2018.

  • What is AgeX Therapeutics's official website?

    The official website for AgeX Therapeutics is agexinc.com.

  • Where are AgeX Therapeutics's headquarters?

    AgeX Therapeutics is headquartered at 1101 Marina Village Parkway, Alameda, CA.

  • How can i contact AgeX Therapeutics?

    AgeX Therapeutics's mailing address is 1101 Marina Village Parkway, Alameda, CA and company can be reached via phone at +51 06718370.

AgeX Therapeutics company profile:

AgeX Therapeutics, Inc.

agexinc.com
Exchange:

AMEX

Full time employees:

4

Industry:

Biotechnology

Sector:

Healthcare

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology. The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California.

1101 Marina Village Parkway
Alameda, CA 94501

CIK: 0001708599
ISIN: US00848H1086
CUSIP: 00848H108